John E. McDonough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John E. McDonough has a total of 465 co-authors. Here are the top co-authors by number of shared publications:
- Bart M. Vanaudenaerde
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
24 shared publications - Stijn E. Verleden
Department of Thoracic and Vascular Surgery & Pneumology, Antwerp University Hospital, Edegem, Belgium; Antwerp Surgical Training Anatomy and Research Centre (ASTARC), University of Antwerp, Antwerpen, Belgium
16 shared publications James C. Hogg
Anesthesiology, Pharmacology & Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada
15 shared publications- Dirk Van Raemdonck
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
13 shared publications - Naftali Kaminski
Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, USA
11 shared publications - Wim A. Wuyts
Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium
11 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 331 (5) , L530-L542
The ferroptosis inhibitor NUPR1 coordinates the mitochondrial response to oxidative stress and cell metabolism during COPD pathogenesis in the lung
COPD is a devastating disease characterized by chronic lung injury and oxidative stress. We provide evidence that NUPR1, an inhibitor of the iron-dependent cell death program ferroptosis, is important for regulating oxidative stress, mitochondrial function, and cell metabolism in AT2 cells of the lung. We further show that loss of NUPR1 in mice contributes to increased oxidative damage and emphysematous changes of the lung, suggesting a critical role of NUPR1 in COPD pathogenesis.
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 331 (5) , L530-L542
Open AccessThe ferroptosis inhibitor NUPR1 coordinates the mitochondrial response to oxidative stress and cell metabolism during COPD pathogenesis in the lung
COPD is a devastating disease characterized by chronic lung injury and oxidative stress. We provide evidence that NUPR1, an inhibitor of the iron-dependent cell death program ferroptosis, is important for regulating oxidative stress, mitochondrial function, and cell metabolism in AT2 cells of the lung. We further show that loss of NUPR1 in mice contributes to increased oxidative damage and emphysematous changes of the lung, suggesting a critical role of NUPR1 in COPD pathogenesis.
- Open Access
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Computational fluid dynamics analyses of the airway tree during inspiration and expiration in moderate and end-stage COPD
Background: Small airway disease (SAD) is a defining feature of chronic obstructive pulmonary disease (COPD), but its functional consequences across the whole bronchial tree remain incompletely quantified. We determined how progressive SAD alters lung airflow dynamics during inspiration and expiration, and whether simplified models reproduce the results of anatomically realistic 3D simulations. Methods: Three lung explants, healthy control, moderate (GOLD II), and end-stage (GOLD IV) COPD, were imaged by micro-CT and segmented from the main-bronchus to the small airways. Inspiratory and expiratory computational fluid dynamics (CFD) simulations used matched main-bronchus-flow and terminal-pressure scenarios. A linear Poiseuille model on the same anatomy benchmarked simplified airway representations. Findings: Airways (0·5–2·5 mm) decreased by 22% in GOLD II and 71% in GOLD IV relative to control. At matched inspiratory flow, whole-lung resistance rose from 0·33 (control) to 0·58 (GOLD II) and 2·15 cm H₂O·s/L (GOLD IV). Expiratory resistance exceeded inspiratory resistance by 19% (control), 38% (GOLD II), and 79% (GOLD IV), an asymmetry that widened with severity. Wall shear stress in GOLD IV rose 8-fold during inspiration and 5-fold during expiration vs control. Simplified linear models underestimated CFD-derived driving pressure 3·8- to 6·8-fold and overestimated expiratory outflow 12·6- to 14·3-fold. Interpretation: Whole-lung CFD revealed a severity-dependent airflow burden in COPD that is amplified during expiration and strongly underestimated by linear flow models and simplified airway geometries. These findings provide a quantitative bridge between distal airway pathology and expiratory flow limitation, and underline the need for anatomy-based 3D modelling when assessing SAD.
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessComputational fluid dynamics analyses of the airway tree during inspiration and expiration in moderate and end-stage COPD
Background: Small airway disease (SAD) is a defining feature of chronic obstructive pulmonary disease (COPD), but its functional consequences across the whole bronchial tree remain incompletely quantified. We determined how progressive SAD alters lung airflow dynamics during inspiration and expiration, and whether simplified models reproduce the results of anatomically realistic 3D simulations. Methods: Three lung explants, healthy control, moderate (GOLD II), and end-stage (GOLD IV) COPD, were imaged by micro-CT and segmented from the main-bronchus to the small airways. Inspiratory and expiratory computational fluid dynamics (CFD) simulations used matched main-bronchus-flow and terminal-pressure scenarios. A linear Poiseuille model on the same anatomy benchmarked simplified airway representations. Findings: Airways (0·5–2·5 mm) decreased by 22% in GOLD II and 71% in GOLD IV relative to control. At matched inspiratory flow, whole-lung resistance rose from 0·33 (control) to 0·58 (GOLD II) and 2·15 cm H₂O·s/L (GOLD IV). Expiratory resistance exceeded inspiratory resistance by 19% (control), 38% (GOLD II), and 79% (GOLD IV), an asymmetry that widened with severity. Wall shear stress in GOLD IV rose 8-fold during inspiration and 5-fold during expiration vs control. Simplified linear models underestimated CFD-derived driving pressure 3·8- to 6·8-fold and overestimated expiratory outflow 12·6- to 14·3-fold. Interpretation: Whole-lung CFD revealed a severity-dependent airflow burden in COPD that is amplified during expiration and strongly underestimated by linear flow models and simplified airway geometries. These findings provide a quantitative bridge between distal airway pathology and expiratory flow limitation, and underline the need for anatomy-based 3D modelling when assessing SAD.
- 2 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2502380
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction
Background: Chronic lung allograft dysfunction (CLAD) is the leading cause of late mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS) are the main underlying clinical entities. Their molecular and cellular signatures are unclear and, therefore, we aimed to identify molecular programmes associated with morphological disease severity in CLAD. Methods: We performed high-resolution imaging-based gene expression profiling of 128 lung samples from explanted CLAD and donor lungs, using weighted gene co-expression network analysis, cellular and pathway enrichment, and hub gene identification. Findings were validated across four datasets, including a murine transplant model, human BOS lungs, transbronchial biopsies, and bronchoalveolar lavage fluid of lung transplant recipients. Results: Unsupervised clustering revealed two transcriptomic CLAD endotypes aligning with mild-fibrotic (BOS, mild RAS) and advanced-fibrotic disease (moderate/severe RAS). Samples from the same patient often diverged molecularly, underscoring intra-patient heterogeneity and limitations of current phenotypical classification. Five molecular programmes emerged: (1) epithelial stress and innate immunity in early-fibrotic CLAD, (2) progressive adaptive immunity and cytotoxicity in advanced CLAD, (3) transient extracellular matrix remodelling, (4) progressive endothelial loss/dysfunction, and (5) progressive loss of homeostasis, wherein multiple potential druggable targets were detected. Finally, we identified a 26 CLAD hub gene-panel, that showed robust diagnostic performance to discriminate CLAD. Conclusion: CLAD is a spatially heterogeneous, yet molecularly continuous disease process, wherein BOS and RAS represent variable stages of a shared immunopathological continuum. Our findings support the development of lung-specific molecular classifiers to guide diagnostics and reveal novel targets for personalised therapies in transplantation.
- 2 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2502380
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction
Background: Chronic lung allograft dysfunction (CLAD) is the leading cause of late mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS) are the main underlying clinical entities. Their molecular and cellular signatures are unclear and, therefore, we aimed to identify molecular programmes associated with morphological disease severity in CLAD. Methods: We performed high-resolution imaging-based gene expression profiling of 128 lung samples from explanted CLAD and donor lungs, using weighted gene co-expression network analysis, cellular and pathway enrichment, and hub gene identification. Findings were validated across four datasets, including a murine transplant model, human BOS lungs, transbronchial biopsies, and bronchoalveolar lavage fluid of lung transplant recipients. Results: Unsupervised clustering revealed two transcriptomic CLAD endotypes aligning with mild-fibrotic (BOS, mild RAS) and advanced-fibrotic disease (moderate/severe RAS). Samples from the same patient often diverged molecularly, underscoring intra-patient heterogeneity and limitations of current phenotypical classification. Five molecular programmes emerged: (1) epithelial stress and innate immunity in early-fibrotic CLAD, (2) progressive adaptive immunity and cytotoxicity in advanced CLAD, (3) transient extracellular matrix remodelling, (4) progressive endothelial loss/dysfunction, and (5) progressive loss of homeostasis, wherein multiple potential druggable targets were detected. Finally, we identified a 26 CLAD hub gene-panel, that showed robust diagnostic performance to discriminate CLAD. Conclusion: CLAD is a spatially heterogeneous, yet molecularly continuous disease process, wherein BOS and RAS represent variable stages of a shared immunopathological continuum. Our findings support the development of lung-specific molecular classifiers to guide diagnostics and reveal novel targets for personalised therapies in transplantation.
- Open Access
- 16 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
CT-derived pulmonary blood volume distribution may be modifiable in asthma
Background: A smaller relative volume of the peripheral pulmonary vasculature in asthma, termed “vascular pruning”, has been linked to greater disease severity, exacerbations, and airflow obstruction. It is not known if this is reversible. Therefore, the study objective was to determine if “loss” of computed tomography (CT) measures of peripheral pulmonary vasculature is a modifiable feature of asthma pathophysiology by assessing its response to dupilumab. Methods: Twenty-seven adults with moderate-to-severe asthma received dupilumab (n=19) or placebo (n=8) every 2-weeks for 16-weeks. Chest CT scans acquired at baseline and follow-up were analyzed to quantify pulmonary blood vessel volumes categorized by cross-sectional area (≤5 mm 2 as BV5 and ≥10 mm 2 as BV10). These volumes were reported relative to the total blood volume (TBV) as BV5% and BV10%. Change in blood vessel volumes from baseline to follow-up were evaluated and correlated with changes in patient-reported outcomes, type-2 inflammatory biomarkers, and measurements of airway structure and function. Results: Following dupilumab treatment (but not placebo), BV5% increased by 1.0% (95% CI: −0.2% to 4.5%, p=0.02) and BV10% decreased by 1.0% (95% CI: −3.6% to 0.7%, p=0.03). The between-group difference in median change was 3.0% for BV5% (95% CI: 0.6% to 5.5%, p=0.008) and −3.0% for BV10% (95% CI: −5.2% to −1.0%, p=0.007). In dupilumab-treated participants, the increase in BV5% and decrease in BV10% was associated with improved ACQ-5, FEV 1 , FeNO, and sputum eosinophil percent (all p<0.05). Conclusion: A redistribution of pulmonary blood volume toward smaller vessels was observed following dupilumab, suggesting that CT-derived pulmonary vascular measurements may be modifiable in asthma.
- 16 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Open AccessCT-derived pulmonary blood volume distribution may be modifiable in asthma
Background: A smaller relative volume of the peripheral pulmonary vasculature in asthma, termed “vascular pruning”, has been linked to greater disease severity, exacerbations, and airflow obstruction. It is not known if this is reversible. Therefore, the study objective was to determine if “loss” of computed tomography (CT) measures of peripheral pulmonary vasculature is a modifiable feature of asthma pathophysiology by assessing its response to dupilumab. Methods: Twenty-seven adults with moderate-to-severe asthma received dupilumab (n=19) or placebo (n=8) every 2-weeks for 16-weeks. Chest CT scans acquired at baseline and follow-up were analyzed to quantify pulmonary blood vessel volumes categorized by cross-sectional area (≤5 mm 2 as BV5 and ≥10 mm 2 as BV10). These volumes were reported relative to the total blood volume (TBV) as BV5% and BV10%. Change in blood vessel volumes from baseline to follow-up were evaluated and correlated with changes in patient-reported outcomes, type-2 inflammatory biomarkers, and measurements of airway structure and function. Results: Following dupilumab treatment (but not placebo), BV5% increased by 1.0% (95% CI: −0.2% to 4.5%, p=0.02) and BV10% decreased by 1.0% (95% CI: −3.6% to 0.7%, p=0.03). The between-group difference in median change was 3.0% for BV5% (95% CI: 0.6% to 5.5%, p=0.008) and −3.0% for BV10% (95% CI: −5.2% to −1.0%, p=0.007). In dupilumab-treated participants, the increase in BV5% and decrease in BV10% was associated with improved ACQ-5, FEV 1 , FeNO, and sputum eosinophil percent (all p<0.05). Conclusion: A redistribution of pulmonary blood volume toward smaller vessels was observed following dupilumab, suggesting that CT-derived pulmonary vascular measurements may be modifiable in asthma.
- Open Access
- 23 January 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
The IBEX knowledge-base a community resource enabling adoption and development of immunofluorescence imaging methods
The iterative bleaching extends multiplexity (IBEX) Knowledge-Base is a central portal for researchers adopting IBEX and related 2D and 3D immunofluorescence imaging methods. The design of the Knowledge-Base is modeled after efforts in the open-source software community and includes three facets: a development platform (GitHub), static website, and service for data archiving. The Knowledge-Base facilitates the practice of open science throughout the research life cycle by providing validation data for recommended and non-recommended reagents, such as primary and secondary antibodies. In addition to reporting negative data, the Knowledge-Base empowers method adoption and evolution by providing a venue for sharing protocols, videos, datasets, software, and publications. A dedicated discussion forum fosters a sense of community among researchers while addressing questions not covered in published manuscripts. Together, scientists from around the world are advancing scientific discovery at a faster pace, reducing wasted time and effort, and instilling greater confidence in the resulting data.
- 23 January 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessThe IBEX knowledge-base a community resource enabling adoption and development of immunofluorescence imaging methods
The iterative bleaching extends multiplexity (IBEX) Knowledge-Base is a central portal for researchers adopting IBEX and related 2D and 3D immunofluorescence imaging methods. The design of the Knowledge-Base is modeled after efforts in the open-source software community and includes three facets: a development platform (GitHub), static website, and service for data archiving. The Knowledge-Base facilitates the practice of open science throughout the research life cycle by providing validation data for recommended and non-recommended reagents, such as primary and secondary antibodies. In addition to reporting negative data, the Knowledge-Base empowers method adoption and evolution by providing a venue for sharing protocols, videos, datasets, software, and publications. A dedicated discussion forum fosters a sense of community among researchers while addressing questions not covered in published manuscripts. Together, scientists from around the world are advancing scientific discovery at a faster pace, reducing wasted time and effort, and instilling greater confidence in the resulting data.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (12) , 2307-2317
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage Chronic Obstructive Pulmonary Disease
Rationale: The precise nature of small airway obstructions in chronic obstructive pulmonary disease (COPD) remains poorly understood, especially at early disease stages. Objectives: This study aimed to characterize small airway obstructions and numbers up to the terminal bronchioles (TBs) in smokers with limited emphysema and end-stage COPD. We hypothesized that obstruction subtypes would differ in morphology, nature, and number from early to end-stage COPD. Methods: Whole lungs were inflated and processed from seven control donors (control: declined for extrapulmonary reasons); from eight donors with a history of smoking, of whom three had 5% emphysema (smokers with emphysema); and from eight patients with end-stage COPD. Micro–computed tomography of tissue was used to assess number of TBs, aerated TBs, and number and type of obstructions and was cross-correlated with histopathology. Measurements and Main Results: Obstructions were mainly present in smokers with emphysema and patients with COPD, resulting in less aerated TBs. On the basis of emphysema extent, more nonaerated TBs were present in regions with no emphysema than in regions with mild emphysema; however, destruction was more prominent in mild emphysema. Multiple types of obstructions were identified, comprising occlusions, webs, and collapses. In smokers with emphysema, obstructions primarily comprised webs and occlusions, whereas all obstruction types were present in COPD. On histopathology, obstructions were identified as mucus plugs. Conclusions: Multiple types of obstruction characterized as mucus plugs were identified in smokers with emphysema and patients with end-stage COPD. Their morphology, nature, and number evolved from smokers with emphysema to end-stage COPD. A shift from obstruction-dominant dysfunction to destruction-dominant pathology was found in smokers on the basis of emphysema presence.
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (12) , 2307-2317
Open AccessDistinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage Chronic Obstructive Pulmonary Disease
Rationale: The precise nature of small airway obstructions in chronic obstructive pulmonary disease (COPD) remains poorly understood, especially at early disease stages. Objectives: This study aimed to characterize small airway obstructions and numbers up to the terminal bronchioles (TBs) in smokers with limited emphysema and end-stage COPD. We hypothesized that obstruction subtypes would differ in morphology, nature, and number from early to end-stage COPD. Methods: Whole lungs were inflated and processed from seven control donors (control: declined for extrapulmonary reasons); from eight donors with a history of smoking, of whom three had 5% emphysema (smokers with emphysema); and from eight patients with end-stage COPD. Micro–computed tomography of tissue was used to assess number of TBs, aerated TBs, and number and type of obstructions and was cross-correlated with histopathology. Measurements and Main Results: Obstructions were mainly present in smokers with emphysema and patients with COPD, resulting in less aerated TBs. On the basis of emphysema extent, more nonaerated TBs were present in regions with no emphysema than in regions with mild emphysema; however, destruction was more prominent in mild emphysema. Multiple types of obstructions were identified, comprising occlusions, webs, and collapses. In smokers with emphysema, obstructions primarily comprised webs and occlusions, whereas all obstruction types were present in COPD. On histopathology, obstructions were identified as mucus plugs. Conclusions: Multiple types of obstruction characterized as mucus plugs were identified in smokers with emphysema and patients with end-stage COPD. Their morphology, nature, and number evolved from smokers with emphysema to end-stage COPD. A shift from obstruction-dominant dysfunction to destruction-dominant pathology was found in smokers on the basis of emphysema presence.
- Open Access
Alveolar epithelial cell plasticity and injury memory in human pulmonary fibrosis
Acute and repetitive lung epithelial injury can lead to irreversible and even progressive pulmonary fibrosis; Idiopathic pulmonary fibrosis (IPF) is a fatal disease and quintessential example of this phenomenon. The composition of epithelial cells in human pulmonary fibrosis – irrespective of disease etiology – is marked by the presence of Aberrant Basaloid cells: an abnormal cell phenotype with pro-fibrotic and senescent features, localized to the surface of fibrotic lesions. Despite their relevance to human pulmonary fibrosis, the exotic molecular profile of Aberrant Basaloid cells has obscured their etiology, preventing insights into how or why these cells emerge with fibrosis. Here we identify cellular intermediaries between Aberrant Basaloid and normal alveolar epithelial cells in human IPF tissue. We track the emergence of Aberrant Basaloid cells from alveolar epithelial cells ex vivo and uncover a role for similar cells in epithelial regeneration under normal conditions. Lastly, we characterize the epigenetic changes that distinguish Aberrant Basaloid cells from their progenitors and identify hallmarks of AP-1 injury memory retention. This study elucidates the phenomenon of maladaptive epithelial plasticity and regeneration in pulmonary fibrosis and re-contextualizes therapeutic strategies for epithelial dysfunction.
Open AccessAlveolar epithelial cell plasticity and injury memory in human pulmonary fibrosis
Acute and repetitive lung epithelial injury can lead to irreversible and even progressive pulmonary fibrosis; Idiopathic pulmonary fibrosis (IPF) is a fatal disease and quintessential example of this phenomenon. The composition of epithelial cells in human pulmonary fibrosis – irrespective of disease etiology – is marked by the presence of Aberrant Basaloid cells: an abnormal cell phenotype with pro-fibrotic and senescent features, localized to the surface of fibrotic lesions. Despite their relevance to human pulmonary fibrosis, the exotic molecular profile of Aberrant Basaloid cells has obscured their etiology, preventing insights into how or why these cells emerge with fibrosis. Here we identify cellular intermediaries between Aberrant Basaloid and normal alveolar epithelial cells in human IPF tissue. We track the emergence of Aberrant Basaloid cells from alveolar epithelial cells ex vivo and uncover a role for similar cells in epithelial regeneration under normal conditions. Lastly, we characterize the epigenetic changes that distinguish Aberrant Basaloid cells from their progenitors and identify hallmarks of AP-1 injury memory retention. This study elucidates the phenomenon of maladaptive epithelial plasticity and regeneration in pulmonary fibrosis and re-contextualizes therapeutic strategies for epithelial dysfunction.
- Open Access
- 3 April 2025
- Published by Elsevier in EBioMedicine
- Vol. 114, 105670
Computational fluid dynamics of small airway disease in chronic obstructive pulmonary disease
- 3 April 2025
- Published by Elsevier in EBioMedicine
- Vol. 114, 105670
Open AccessComputational fluid dynamics of small airway disease in chronic obstructive pulmonary disease
- 1 April 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (4) , 523-532
Airway Remodeling in Cystic Fibrosis Is Heterogeneous
Rationale: Cystic fibrosis (CF) is characterized by bronchiectasis on imaging, while functionally evolving toward obstructive impairment. Despite its assumed importance in CF, small airway remodeling and its relation to bronchiectasis remains poorly understood. Objectives: The aim of our study was to explore both large and small airway disease morphometrically, by using detailed imaging techniques, such as ex vivo high-resolution computed tomography (HRCT) and micro–computed tomography (μCT), and histological analysis in advanced CF. Methods: On HRCT (600 μm; CF, n = 21; control, n = 6) and μCT (150 μm; CF, n = 3; control, n = 1) scans of inflated explanted lungs, the ratio of visible airway volume to total lung volume (AV%) was calculated as a marker of bronchiectasis, while airway segmentation was used for generation analysis. Clinical data were retrospectively collected. On μCT (8.5 μm) images of lung cores (±2.8 cm3), extracted randomly from each lobe (three per lobe), distal airway (DA) diameter, number of airway collapses, and number of open terminal bronchioles per milliliter were analyzed. Morphometric analysis was supplemented with histological analysis of DA collapse. Results: AV% on HRCT was heterogeneous among CF lungs (0.7–4.6%), overlapping with controls (0.4–1.2%). However, the pattern of airway loss on μCT was homogeneous among CF lungs and most pronounced from generations 9–16. AV% did not correlate with the number of open terminal bronchioles per milliliter or percentage predicted forced expiratory volume in 1 second, which correlated with each other. Open DAs in CF lungs were narrowed compared with DA in controls. On the other hand, collapsed DAs in CF lungs showed varying degrees of proximal dilation, with DA diameter correlating with AV%. On histology, collapsed CF DAs showed constrictive bronchiolitis. Conclusions: Airway remodeling in end-stage CF is heterogeneous, ranging from minimal bronchiectasis, overlapping with control lungs, to extensive bronchiectasis with small airway dilation. However, the degree of bronchiectasis is unrelated to functional impairment or the amount of small airway loss, underscoring the importance of small airway disease.
- 1 April 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (4) , 523-532
Airway Remodeling in Cystic Fibrosis Is Heterogeneous
Rationale: Cystic fibrosis (CF) is characterized by bronchiectasis on imaging, while functionally evolving toward obstructive impairment. Despite its assumed importance in CF, small airway remodeling and its relation to bronchiectasis remains poorly understood. Objectives: The aim of our study was to explore both large and small airway disease morphometrically, by using detailed imaging techniques, such as ex vivo high-resolution computed tomography (HRCT) and micro–computed tomography (μCT), and histological analysis in advanced CF. Methods: On HRCT (600 μm; CF, n = 21; control, n = 6) and μCT (150 μm; CF, n = 3; control, n = 1) scans of inflated explanted lungs, the ratio of visible airway volume to total lung volume (AV%) was calculated as a marker of bronchiectasis, while airway segmentation was used for generation analysis. Clinical data were retrospectively collected. On μCT (8.5 μm) images of lung cores (±2.8 cm3), extracted randomly from each lobe (three per lobe), distal airway (DA) diameter, number of airway collapses, and number of open terminal bronchioles per milliliter were analyzed. Morphometric analysis was supplemented with histological analysis of DA collapse. Results: AV% on HRCT was heterogeneous among CF lungs (0.7–4.6%), overlapping with controls (0.4–1.2%). However, the pattern of airway loss on μCT was homogeneous among CF lungs and most pronounced from generations 9–16. AV% did not correlate with the number of open terminal bronchioles per milliliter or percentage predicted forced expiratory volume in 1 second, which correlated with each other. Open DAs in CF lungs were narrowed compared with DA in controls. On the other hand, collapsed DAs in CF lungs showed varying degrees of proximal dilation, with DA diameter correlating with AV%. On histology, collapsed CF DAs showed constrictive bronchiolitis. Conclusions: Airway remodeling in end-stage CF is heterogeneous, ranging from minimal bronchiectasis, overlapping with control lungs, to extensive bronchiectasis with small airway dilation. However, the degree of bronchiectasis is unrelated to functional impairment or the amount of small airway loss, underscoring the importance of small airway disease.
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (3) , L456-L462
Epigenetic age acceleration in idiopathic pulmonary fibrosis revealed by DNA methylation clocks
Using epigenetic clocks, we found a notable acceleration of biological aging in IPF tissues, particularly in DunedinPACE, suggesting that the biological aging process in IPF is accelerated and closely related to the severity of the disease. The study also underscores DNA methylation’s potential as a biomarker for IPF, as well as the dynamics of epigenetic aging and the need to consider biological age in medical research and healthcare.
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (3) , L456-L462
Epigenetic age acceleration in idiopathic pulmonary fibrosis revealed by DNA methylation clocks
Using epigenetic clocks, we found a notable acceleration of biological aging in IPF tissues, particularly in DunedinPACE, suggesting that the biological aging process in IPF is accelerated and closely related to the severity of the disease. The study also underscores DNA methylation’s potential as a biomarker for IPF, as well as the dynamics of epigenetic aging and the need to consider biological age in medical research and healthcare.